ATE246937T1 - Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff - Google Patents

Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Info

Publication number: ATE246937T1
Authority: AT; Austria
Prior art keywords: liquid vaccine; threalose; stabilization; vaccine composition; liquid
Prior art date: 1999-03-23

Application number

AT00912734T

Other languages

English (en)

Inventor

Graf Sandrine Lentsch

Jean-Rene Cartier

Original Assignee

Aventis Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-23

Filing date

2000-03-23

Publication date

2003-08-15

2000-03-23 Application filed by Aventis Pasteur filed Critical Aventis Pasteur

2003-08-15 Application granted granted Critical

2003-08-15 Publication of ATE246937T1 publication Critical patent/ATE246937T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 4
239000007788 liquid Substances 0.000 title abstract 3
230000006641 stabilisation Effects 0.000 title 1
238000011105 stabilization Methods 0.000 title 1
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
102000014914 Carrier Proteins Human genes 0.000 abstract 1
108010078791 Carrier Proteins Proteins 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
150000004676 glycans Chemical class 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
230000003019 stabilising effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT00912734T 1999-03-23 2000-03-23 Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff ATE246937T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9903765A FR2791895B1 (fr)	1999-03-23	1999-03-23	Utilisation de trehalose pour stabiliser un vaccin liquide
PCT/FR2000/000730 WO2000056365A1 (fr)	1999-03-23	2000-03-23	Utilisation de trehalose pour stabiliser un vaccin liquide

Publications (1)

Publication Number	Publication Date
ATE246937T1 true ATE246937T1 (de)	2003-08-15

Family

ID=9543654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00912734T ATE246937T1 (de)	1999-03-23	2000-03-23	Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff

Country Status (11)

Country	Link
EP (1)	EP1163008B1 (de)
JP (1)	JP2002540079A (de)
AT (1)	ATE246937T1 (de)
AU (1)	AU3438900A (de)
CA (1)	CA2366869A1 (de)
DE (1)	DE60004496T2 (de)
DK (1)	DK1163008T3 (de)
ES (1)	ES2200845T3 (de)
FR (1)	FR2791895B1 (de)
PT (1)	PT1163008E (de)
WO (1)	WO2000056365A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0909323B1 (de)	1996-01-04	2007-02-28	Novartis Vaccines and Diagnostics, Inc.	Bakterioferritin aus helicobacter pylori
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
EP2351579B1 (de)	2002-10-11	2016-09-21	Novartis Vaccines and Diagnostics S.r.l.	Poylpeptidimpfstoffe zum breiten Schutz gegen hypervirulente Meningo-kokken-Linien
DK1587537T3 (da)	2003-01-30	2012-07-16	Novartis Ag	Injicerbare vacciner mod multiple meningococ-serogrupper
ES2397923T3 (es)	2003-10-02	2013-03-12	Novartis Ag	Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
GB0406013D0 (en)	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
AU2007251122B2 (en) *	2006-05-12	2013-01-10	Bharat Biotech International Limited	A composition useful as a vaccine
SI2097102T1 (sl)	2006-09-07	2012-09-28	Glaxosmithkline Biolog Sa	Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
AU2008299885C1 (en)	2007-09-14	2015-06-25	Sanofi Pasteur Biologics, Llc	Pharmaceutical compositions containing clostridium difficile toxoids A and B
EP2106788A1 (de)	2008-04-04	2009-10-07	Ipsen Pharma	Flüssige und lyophilisierte Formulierungen
US8974799B2 (en)	2009-09-30	2015-03-10	Novartis Ag	Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
EP2544714A1 (de)	2010-03-10	2013-01-16	GlaxoSmithKline Biologicals S.A.	Impfstoffzusammensetzung
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
GB201016969D0 (en)	2010-10-08	2010-11-24	Genome Res Ltd	Expression system
CA2777431A1 (en)	2011-05-20	2012-11-20	Nitto Denko Corporation	Pharmaceutical composition and method for producing the same
EP2755683B1 (de)	2011-09-14	2019-04-03	GlaxoSmithKline Biologicals SA	Verfahren zur herstellung von saccharidprotein-glykokonjugaten
WO2013083753A2 (en)	2011-12-07	2013-06-13	Institut Pasteur	Identification of a swine parecho-like virus and applications
EP2852414B9 (de)	2012-05-22	2020-12-09	GlaxoSmithKline Biologicals SA	Meningokokken-serogruppe-x-konjugat
FR2992656B1 (fr) *	2012-07-02	2016-10-07	Sanofi Pasteur	Procede de production d'antigenes haemophilus influenzae type b
WO2014009971A2 (en) *	2012-07-07	2014-01-16	Bharat Biotech International Limited	Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
CN104582718B (zh)	2012-10-03	2017-10-24	诺华股份有限公司	免疫原性组合物
ES2677723T3 (es) *	2012-12-28	2018-08-06	Cellestis Limited	Un ensayo de la respuesta inmunológica mediada por células
WO2017175082A1 (en)	2016-04-05	2017-10-12	Gsk Vaccines S.R.L.	Immunogenic compositions
CN109890413B (zh)	2016-09-02	2024-04-16	赛诺菲巴斯德股份有限公司	脑膜炎奈瑟氏菌疫苗
WO2018048869A1 (en)	2016-09-06	2018-03-15	Bioventures, Llc	Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
US12544441B2 (en)	2016-11-01	2026-02-10	Washington University	Compositions comprising CelTOS immunogens and antibodies and method of use thereof
US12398184B2 (en)	2016-11-01	2025-08-26	Washington University	Compositions comprising CelTOS immunogens and antibodies and method of use thereof
EP3369431A1 (de)	2017-03-03	2018-09-05	Treos Bio Kft	Impfstoff
EP3370065A1 (de)	2017-03-03	2018-09-05	Treos Bio Kft	Immunogene peptide
BR112019018307A2 (pt)	2017-03-03	2020-03-31	Treos Bio Zrt	Plataforma para identificação de peptídeos imunogênicos baseada em população
CN113329761A (zh)	2018-09-04	2021-08-31	特雷斯生物有限公司	肽疫苗
GB201814362D0 (en)	2018-09-04	2018-10-17	Treos Bio Zrt	Composition and process for preparing vaccine
US12128094B2 (en)	2018-11-06	2024-10-29	Glaxosmithkline Biologicals Sa	Immunogenic compositions comprising OMVs, an acellular pertussis antigen, a tetanus toxoid and a diphtheria toxoid
GB201908332D0 (en)	2019-06-11	2019-07-24	Univ Oxford Innovation Ltd	Assays and inhibitors of oxygen-dependent N-terminal oxidation
JP2023520562A (ja)	2020-04-03	2023-05-17	ペップティーシーヴァクシーンズリミテッド	コロナウイルスワクチン
GB202004974D0 (en)	2020-04-03	2020-05-20	Treos Bio Ltd	Coronavirus vaccine
WO2022268916A2 (en)	2021-06-23	2022-12-29	Ose Immunotherapeutics	Pan-coronavirus peptide vaccine
GB202109082D0 (en)	2021-06-24	2021-08-11	Univ Oxford Innovation Ltd	Polypeptides and uses thereof
US20250161421A1 (en)	2022-02-03	2025-05-22	CeCaVa GmbH & Co. KG	Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en)	2022-06-14	2022-07-27	Univ Oxford Innovation Ltd	Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2748132A1 (de) *	1977-10-27	1979-05-03	Behringwerke Ag	Stabilisator fuer polysaccharid
US4902506A (en) *	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
IL78775A (en) *	1985-05-15	1992-06-21	Biotech Australia Pty Ltd	Oral vaccines
ES2137310T3 (es) *	1993-05-17	1999-12-16	Akzo Nobel Nv	Vacuna contra una infeccion por streptococcus suis.
JP4142095B2 (ja) *	1994-06-02	2008-08-27	クアドラント・ドラツグ・デリバリー・リミテツド	各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
DE69738271T2 (de) *	1996-09-26	2008-08-28	Merck & Co., Inc.	Rotavirus-impfstoff
US6210683B1 (en) *	1997-09-05	2001-04-03	Merck & Co., Inc.	Stabilizers containing recombinant human serum albumin for live virus vaccines

1999
- 1999-03-23 FR FR9903765A patent/FR2791895B1/fr not_active Expired - Fee Related
2000
- 2000-03-23 AT AT00912734T patent/ATE246937T1/de not_active IP Right Cessation
- 2000-03-23 DK DK00912734T patent/DK1163008T3/da active
- 2000-03-23 JP JP2000606269A patent/JP2002540079A/ja active Pending
- 2000-03-23 EP EP00912734A patent/EP1163008B1/de not_active Expired - Lifetime
- 2000-03-23 AU AU34389/00A patent/AU3438900A/en not_active Abandoned
- 2000-03-23 WO PCT/FR2000/000730 patent/WO2000056365A1/fr not_active Ceased
- 2000-03-23 DE DE60004496T patent/DE60004496T2/de not_active Expired - Fee Related
- 2000-03-23 ES ES00912734T patent/ES2200845T3/es not_active Expired - Lifetime
- 2000-03-23 PT PT00912734T patent/PT1163008E/pt unknown
- 2000-03-23 CA CA002366869A patent/CA2366869A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2200845T3 (es)	2004-03-16
AU3438900A (en)	2000-10-09
EP1163008A1 (de)	2001-12-19
WO2000056365A1 (fr)	2000-09-28
DK1163008T3 (da)	2003-11-17
EP1163008B1 (de)	2003-08-13
DE60004496T2 (de)	2004-04-08
FR2791895B1 (fr)	2001-06-15
PT1163008E (pt)	2003-12-31
FR2791895A1 (fr)	2000-10-13
CA2366869A1 (en)	2000-09-28
DE60004496D1 (de)	2003-09-18
JP2002540079A (ja)	2002-11-26

Legal Events

Date

Code

Title

Description

2003-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1163008

Country of ref document: EP

2009-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60004496D1 (de)	2003-09-18	Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff
UA93855C2 (ru)	2011-03-25	Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
IL210392A0 (en)	2011-03-31	Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof
DE69819332D1 (de)	2003-12-04	VERBESSERTE ANTIKÖRPER GEGEN IgE UND VERFAHREN ZUR VERBESSERUNG VON ANTIKÖRPERN
DE60100473D1 (de)	2003-08-21	Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
DE69936948D1 (de)	2007-10-04	Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
ATE394536T1 (de)	2008-05-15	Textilweichmacherzusammensetzungen und verfahren zur stabilisierung von textilweichmacherzusammensetzungen
DE60018907D1 (de)	2005-04-28	Verfahren und zusammensetzung zur zementierung von bohrlöchern
DE60116322D1 (de)	2006-02-02	Vorrichtung zur aktiven kompensation von aberrationen in einem optischen system
DE69833134D1 (de)	2006-03-30	Verwendung aliphatischer amine zur verminderung von oxalat
DE69431404D1 (de)	2002-10-24	Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE220558T1 (de)	2002-08-15	Verbessertes verfahren zur stabilisierung von proteinen
DE69717413D1 (de)	2003-01-09	Verfahren zur Gewichtsbestimmung von bogenförmigen Trägern
ATE257482T1 (de)	2004-01-15	Verfahren zur stabilisierung von siloxan- verbindungen
MY150893A (en)	2014-03-14	Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DE60230456D1 (de)	2009-01-29	Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
DE69927520D1 (de)	2006-02-09	Verwendung von il-12 antikörpern zur behandlung von psoriasis
DE69835813D1 (de)	2006-10-19	Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE69823711D1 (de)	2004-06-17	Verfahren zur Stabilisierung von Siloxanpolymeren
ATE424217T1 (de)	2009-03-15	Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
ATE274185T1 (de)	2004-09-15	Verfahren und zusammensetzungen zur trennung von biologischen makromolekülen
ATE489466T1 (de)	2010-12-15	Nukleinsäuren zur hemmung der expression von hairless-protein und verfahren zur verwendung davon
WO2002062964A3 (en)	2007-08-02	Ap1 amine oxidase variants
DE69830156D1 (de)	2005-06-16	Zusammensetzungen zur immunverstärkung von impfstoffen
ATE505538T1 (de)	2011-04-15	Dna-vektoren